Premium
Prognostic Value of Soluble Intercellular Adhesion Molecule‐1 (s‐ICAM‐1) in HIV‐Infected Children
Author(s) -
Gaddi E.,
Laucella S.,
Balbaryski J.,
Cantisano C.,
Barboni G.,
Candi M.,
Giraudi V.
Publication year - 2000
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2000.00820.x
Subject(s) - icam 1 , titer , intercellular adhesion molecule 1 , immune system , immunology , beta 2 microglobulin , antibody , disease , immunopathology , intercellular adhesion molecule , intracellular , medicine , cell adhesion molecule , biology , cell adhesion , cell , biochemistry
Central events in the host defence system and immune‐mediated damage are tightly regulated by cell adhesion molecules. Sera from 28 human immunodeficiency virus (HIV)‐1 infected children divided into groups according to disease severity, six seroreverting (SR) children and 25 healthy controls were studied to detect the presence of soluble intercellular adhesion molecule‐1 (s‐ICAM‐1). Soluble ICAM‐1 levels were found to be significantly increased in HIV‐infected children in comparison with SR children or healthy controls. Levels of soluble ICAM‐1 were higher in patients with severe forms of HIV‐infection than in those with a milder form of the disease. Significant differences in titers of s‐ICAM‐1 were recorded between SR children and HIV‐infected children with mild disease or healthy controls. There was a significant correlation between s‐ICAM‐1 levels and the concentrations of beta 2 microglobulin (β2m) and, to a lesser extend, immunoglobulin A levels (IgA). Soluble ICAM‐1 levels didn't change considerably in HIV‐infected children in stable clinical conditions, independently of their clinical stage of the disease, during a follow‐up period of 9–12 months. Conversely, s‐ICAM‐1 levels increased simultaneously with the appearance of new well‐defined clinical disorders or decreased during the improvement of clinical conditions. A significant negative correlation was recorded between the titers of the s‐ICAM‐1 and the CD4 + T‐cell levels. These results suggest that the s‐ICAM‐1 might be another useful tool to evaluate disease progression.